Please ensure Javascript is enabled for purposes of website accessibility

Will Abbott Stock Keep Surging Behind Emerging Markets?

By Dan Carroll - Apr 23, 2013 at 6:35PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

India, Brazil, and other developing nations are squarely in this company's crosshairs.

Abbott Labs(ABT 0.71%) stock has surged this year, shooting up more than 15% since the start of 2013. Despite the company's spinoff of former pharmaceutical firm AbbVie (ABBV -0.47%) -- a move that waved goodbye to its high-growth pharmaceuticals business, including massive immunology blockbuster Humira that pulled in $9 billion in sales last year -- Abbott has still managed to find growth by turning to a new engine: emerging markets.

The company has spread globally, aggressively targeting Brazil in its recent attempt to bid for Ache Labs, one of the country's leading drugmakers. Abbott faces tough competition in the acquisition bid from Pfizer (PFE 3.59%) and Novartis (NVS 0.87%), each of which also want to expand their emerging markets push into Brazil's fast-growing health care market, but Abbott has also done a good job growing in China, India, and more. Is this a strategy that will keep Abbott stock growing enough to support your portfolio's future? Fool contributor Dan Carroll and health care analyst Max Macaluso discuss Abbott's recent international push in the video below and how these moves can pay off for the company.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Abbott Laboratories Stock Quote
Abbott Laboratories
ABT
$113.24 (0.71%) $0.80
Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$52.47 (3.59%) $1.82
Novartis AG Stock Quote
Novartis AG
NVS
$89.42 (0.87%) $0.77
AbbVie Inc. Stock Quote
AbbVie Inc.
ABBV
$151.01 (-0.47%) $0.71

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
331%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/20/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.